arrow
N

Nagio Takigawa

Kawasaki Medical School
H指数:45
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plasma metabolomic profiling to predict durable response and survival with afatinib in EGFR-mutated non-small cell lung cancer: A prospective, multicenter, observational biomarker study

血浆代谢组学分析预测EGFR突变非小细胞肺癌患者接受阿法替尼治疗后的持久缓解和生存:一项前瞻性、多中心、观察性生物标志物研究

2026-11-030
PRE
Impact of antibiotic use on survival in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor and chemotherapy

抗生素使用对接受免疫检查点抑制剂联合化疗的晚期非小细胞肺癌患者生存的影响

2025-08-280
PRE
Plasma cell-free DNA methylation profile before afatinib treatment is associated with progression-free and overall survival of patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer

afatinib治疗前的血浆游离DNA甲基化谱与表皮生长因子受体基因突变阳性非小细胞肺癌患者的无进展生存期和总生存期相关

2025-04-250
OA
Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study)
2023-11-010
OAAI
Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study
2023-06-051
OAAI
Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression

对letter re的回应: 抗生素对非小细胞肺癌患者免疫检查点抑制剂疗效的影响因PD-L1表达而异

2021-11-010
PREAI
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression

抗生素对非小细胞肺癌患者免疫检查点抑制剂疗效的影响基于PD-L1表达的差异

2021-05-0145
PREAI